COGT - Latest News
Cogent Biosciences, Inc. (COGT), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $5.86B. Beta to the broader market is 0.37.
The article list below shows the most recent COGT headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent COGT Headlines
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
globenewswire.com - May 12, 2026
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
globenewswire.com - May 5, 2026
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK tri
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
globenewswire.com - Apr 21, 2026
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com - Apr 17, 2026
– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin to
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
seekingalpha.com - Apr 2, 2026
Cogent Biosciences, Inc. maintains a Buy rating as bezuclastinib demonstrates blockbuster potential in GIST and systemic mastocytosis (SM) indication
How News Affects COGT Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track COGT's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked COGT news questions
- What is the latest COGT news headline?
- The most recent COGT headline (May 12, 2026) is "Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the COGT news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What COGT news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual COGT options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.